Therefore, we conclude that OR51E2 represents a promising therapeutic target protein for the treatment of proliferative RPE disorders, such as proliferative vitreoretinopathy (Andrews et al., 1999; Pennock et al., 2014). Here, OR51E2 is linked to CAPN5-related vitreoretinopathy.